Clinical characteristics and treatment outcome of acute myeloid leukemia in elderly patients in Korea: A retrospective analysis

Hyeon Gyu Yi, Moon Hee Lee, Chul Soo Kim, Junshik Hong, Jinny Park, Jae Hoon Lee, Bo Ram Han, Ho Young Kim, Dae Young Zang, Se Hyung Kim, Seong Kyu Park, Dae Sik Hong, Guk Jin Lee, Jong Youl Jin

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background: The clinical characteristics of elderly patients with AML differ from those of younger patients, resulting in poorer survival and treatment outcomes. We analyzed retrospectively the clinical data of AML patients 65 years old and above to describe patients' characteristics and treatment patterns, and to define meaningful prognostic factors of survival in the Korean population. Methods: Basic patients' characteristics, clinical outcomes according to treatments, and prognostic factors associated with survival and treatment intensity were examined in a total of 168 patients diagnosed in 5 institutes between 1996 and 2012 as having AML. Results: Herein, 84 patients (50.0%) received high-intensity regimens (HIR), 18 (10.7%) received low-intensity regimens (LIR), and 66 (39.3%) received supportive care (SC) only. The median survival of all patients was 4.5 months; and median survival times with HIR, LIR, and SC were 6.8 months, 10.2 months, and 1.6 months, respectively. Median survival times with HIR and LIR were significantly longer than that with SC (P<0.0001 and P=0.006, respectively). Multivariate analysis identified age, Eastern Cooperative Oncology Group-performance status (ECOG-PS), hemoglobin (Hb) level, and serum creatinine (Cr) level as statistically significant prognostic factors for survival. In the HIR group, prognostic factors for survival were ECOG-PS, Hb level, and C-reactive protein level. Conclusion: Even in elderly AML patients, an intensive treatment regimen could be beneficial with careful patient selection. Further prospective studies designed to identify specific prognostic factors are required to establish an optimal treatment strategy for elderly AML patients.

Original languageEnglish
Pages (from-to)95-99
Number of pages5
JournalBlood Research
Volume49
Issue number2
DOIs
StatePublished - 1 Jan 2014

Fingerprint

Korea
Acute Myeloid Leukemia
Survival
Hemoglobin C
Therapeutics
C-Reactive Protein
Patient Selection
Creatinine
Hemoglobins
Multivariate Analysis
Prospective Studies

Keywords

  • Acute myeloid leukemia
  • Chemotherapy
  • Elderly
  • Prognosis
  • Survival

Cite this

Yi, Hyeon Gyu ; Lee, Moon Hee ; Kim, Chul Soo ; Hong, Junshik ; Park, Jinny ; Lee, Jae Hoon ; Han, Bo Ram ; Kim, Ho Young ; Zang, Dae Young ; Kim, Se Hyung ; Park, Seong Kyu ; Hong, Dae Sik ; Lee, Guk Jin ; Jin, Jong Youl. / Clinical characteristics and treatment outcome of acute myeloid leukemia in elderly patients in Korea : A retrospective analysis. In: Blood Research. 2014 ; Vol. 49, No. 2. pp. 95-99.
@article{b6e7b410de0a41079b58becf66205d82,
title = "Clinical characteristics and treatment outcome of acute myeloid leukemia in elderly patients in Korea: A retrospective analysis",
abstract = "Background: The clinical characteristics of elderly patients with AML differ from those of younger patients, resulting in poorer survival and treatment outcomes. We analyzed retrospectively the clinical data of AML patients 65 years old and above to describe patients' characteristics and treatment patterns, and to define meaningful prognostic factors of survival in the Korean population. Methods: Basic patients' characteristics, clinical outcomes according to treatments, and prognostic factors associated with survival and treatment intensity were examined in a total of 168 patients diagnosed in 5 institutes between 1996 and 2012 as having AML. Results: Herein, 84 patients (50.0{\%}) received high-intensity regimens (HIR), 18 (10.7{\%}) received low-intensity regimens (LIR), and 66 (39.3{\%}) received supportive care (SC) only. The median survival of all patients was 4.5 months; and median survival times with HIR, LIR, and SC were 6.8 months, 10.2 months, and 1.6 months, respectively. Median survival times with HIR and LIR were significantly longer than that with SC (P<0.0001 and P=0.006, respectively). Multivariate analysis identified age, Eastern Cooperative Oncology Group-performance status (ECOG-PS), hemoglobin (Hb) level, and serum creatinine (Cr) level as statistically significant prognostic factors for survival. In the HIR group, prognostic factors for survival were ECOG-PS, Hb level, and C-reactive protein level. Conclusion: Even in elderly AML patients, an intensive treatment regimen could be beneficial with careful patient selection. Further prospective studies designed to identify specific prognostic factors are required to establish an optimal treatment strategy for elderly AML patients.",
keywords = "Acute myeloid leukemia, Chemotherapy, Elderly, Prognosis, Survival",
author = "Yi, {Hyeon Gyu} and Lee, {Moon Hee} and Kim, {Chul Soo} and Junshik Hong and Jinny Park and Lee, {Jae Hoon} and Han, {Bo Ram} and Kim, {Ho Young} and Zang, {Dae Young} and Kim, {Se Hyung} and Park, {Seong Kyu} and Hong, {Dae Sik} and Lee, {Guk Jin} and Jin, {Jong Youl}",
year = "2014",
month = "1",
day = "1",
doi = "10.5045/br.2014.49.2.95",
language = "English",
volume = "49",
pages = "95--99",
journal = "Blood Research",
issn = "2287-979X",
publisher = "Korean Society of Hematology",
number = "2",

}

Yi, HG, Lee, MH, Kim, CS, Hong, J, Park, J, Lee, JH, Han, BR, Kim, HY, Zang, DY, Kim, SH, Park, SK, Hong, DS, Lee, GJ & Jin, JY 2014, 'Clinical characteristics and treatment outcome of acute myeloid leukemia in elderly patients in Korea: A retrospective analysis', Blood Research, vol. 49, no. 2, pp. 95-99. https://doi.org/10.5045/br.2014.49.2.95

Clinical characteristics and treatment outcome of acute myeloid leukemia in elderly patients in Korea : A retrospective analysis. / Yi, Hyeon Gyu; Lee, Moon Hee; Kim, Chul Soo; Hong, Junshik; Park, Jinny; Lee, Jae Hoon; Han, Bo Ram; Kim, Ho Young; Zang, Dae Young; Kim, Se Hyung; Park, Seong Kyu; Hong, Dae Sik; Lee, Guk Jin; Jin, Jong Youl.

In: Blood Research, Vol. 49, No. 2, 01.01.2014, p. 95-99.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Clinical characteristics and treatment outcome of acute myeloid leukemia in elderly patients in Korea

T2 - A retrospective analysis

AU - Yi, Hyeon Gyu

AU - Lee, Moon Hee

AU - Kim, Chul Soo

AU - Hong, Junshik

AU - Park, Jinny

AU - Lee, Jae Hoon

AU - Han, Bo Ram

AU - Kim, Ho Young

AU - Zang, Dae Young

AU - Kim, Se Hyung

AU - Park, Seong Kyu

AU - Hong, Dae Sik

AU - Lee, Guk Jin

AU - Jin, Jong Youl

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Background: The clinical characteristics of elderly patients with AML differ from those of younger patients, resulting in poorer survival and treatment outcomes. We analyzed retrospectively the clinical data of AML patients 65 years old and above to describe patients' characteristics and treatment patterns, and to define meaningful prognostic factors of survival in the Korean population. Methods: Basic patients' characteristics, clinical outcomes according to treatments, and prognostic factors associated with survival and treatment intensity were examined in a total of 168 patients diagnosed in 5 institutes between 1996 and 2012 as having AML. Results: Herein, 84 patients (50.0%) received high-intensity regimens (HIR), 18 (10.7%) received low-intensity regimens (LIR), and 66 (39.3%) received supportive care (SC) only. The median survival of all patients was 4.5 months; and median survival times with HIR, LIR, and SC were 6.8 months, 10.2 months, and 1.6 months, respectively. Median survival times with HIR and LIR were significantly longer than that with SC (P<0.0001 and P=0.006, respectively). Multivariate analysis identified age, Eastern Cooperative Oncology Group-performance status (ECOG-PS), hemoglobin (Hb) level, and serum creatinine (Cr) level as statistically significant prognostic factors for survival. In the HIR group, prognostic factors for survival were ECOG-PS, Hb level, and C-reactive protein level. Conclusion: Even in elderly AML patients, an intensive treatment regimen could be beneficial with careful patient selection. Further prospective studies designed to identify specific prognostic factors are required to establish an optimal treatment strategy for elderly AML patients.

AB - Background: The clinical characteristics of elderly patients with AML differ from those of younger patients, resulting in poorer survival and treatment outcomes. We analyzed retrospectively the clinical data of AML patients 65 years old and above to describe patients' characteristics and treatment patterns, and to define meaningful prognostic factors of survival in the Korean population. Methods: Basic patients' characteristics, clinical outcomes according to treatments, and prognostic factors associated with survival and treatment intensity were examined in a total of 168 patients diagnosed in 5 institutes between 1996 and 2012 as having AML. Results: Herein, 84 patients (50.0%) received high-intensity regimens (HIR), 18 (10.7%) received low-intensity regimens (LIR), and 66 (39.3%) received supportive care (SC) only. The median survival of all patients was 4.5 months; and median survival times with HIR, LIR, and SC were 6.8 months, 10.2 months, and 1.6 months, respectively. Median survival times with HIR and LIR were significantly longer than that with SC (P<0.0001 and P=0.006, respectively). Multivariate analysis identified age, Eastern Cooperative Oncology Group-performance status (ECOG-PS), hemoglobin (Hb) level, and serum creatinine (Cr) level as statistically significant prognostic factors for survival. In the HIR group, prognostic factors for survival were ECOG-PS, Hb level, and C-reactive protein level. Conclusion: Even in elderly AML patients, an intensive treatment regimen could be beneficial with careful patient selection. Further prospective studies designed to identify specific prognostic factors are required to establish an optimal treatment strategy for elderly AML patients.

KW - Acute myeloid leukemia

KW - Chemotherapy

KW - Elderly

KW - Prognosis

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=84903523309&partnerID=8YFLogxK

U2 - 10.5045/br.2014.49.2.95

DO - 10.5045/br.2014.49.2.95

M3 - Article

AN - SCOPUS:84903523309

VL - 49

SP - 95

EP - 99

JO - Blood Research

JF - Blood Research

SN - 2287-979X

IS - 2

ER -